hackint0sh/New-Dataset huggingface dataset:
* Site/phone visits are at a monthly interval. conditions: Bronchiectasis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 300 type: ESTIMATED name: Itepekimab (SAR440340) name: Placebo measure: Annualized rate of moderate or severe Pulmonary exacerbations (PEs) over the treatment period measure: Time to first moderate or severe PE over the treatment period measure: Percentage of participants who are PE free over the treatment period measure: Annualized rate of severe PEs over the treatment period measure: Percentage of participants who are severe PE free over the treatment period measure: Time to first severe PE over the treatment period measure: Change From Baseline in FEV1 at Week 8 and Week 24 measure: Number of days of new and/or added (in participants with maintenance antibiotic use) antibiotic use measure: Change from Baseline in QOL-B Respiratory Symptoms Domain Score in Adult Participants at Week 24 measure: Change from baseline in SGRQ total score at Week 24 measure: Percentage of participants with a decrease from baseline of at least 4 points in SGRQ total score at Week 24 measure: Incidence of TEAEs, AESIs, SAEs, and AEs leading to permanent study treatment discontinuation in the treatment-emergent period measure: Serum concentrations of itepekimab from baseline to end of study measure: Incidence of treatment-emergent anti-itepekimab antibodies (ADA) responses throughout the study sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Allianz Research Institute Site Number : 8400013 status: RECRUITING city: Westminster state: California zip: 92683 country: United States lat: 33.75918 lon: -118.00673 facility: Southeastern Research Center Site Number : 8400008 status: RECRUITING city: Winston-Salem state: North Carolina zip: 27103 country: United States lat: 36.09986 lon: -80.24422 facility: Investigational Site Number : 8260008 status: RECRUITING city: Norwich state: Norfolk zip: NR4 7UY country: United Kingdom lat: 52.62783 lon: 1.29834 facility: Investigational Site Number : 8260003 status: RECRUITING city: Tyne And Wear state: North Tyneside zip: NE29 8NH country: United Kingdom facility: Investigational Site Number : 8260001 status: RECRUITING city: Newcastle upon Tyne zip: NE7 7DN country: United Kingdom lat: 54.97328 lon: -1.61396 facility: Investigational Site Number : 8260005 status: RECRUITING city: Reading zip: RG1 5AN country: United Kingdom lat: 51.45625 lon: -0.97113 hasResults: False
nctId: NCT06280378 id: CP-KL003-003/01 briefTitle: A Phase I/II Clinical Study of the KL003 Cell Injection in β-Thalassemia Major Participants overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-05 date: 2027-05 date: 2024-02-28 date: 2024-02-28 name: Kanglin Biotechnology (Hangzhou) Co., Ltd. class: INDUSTRY briefSummary: This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major. conditions: Transfusion-dependent Beta-Thalassemia studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 41 type: ESTIMATED name: KL003 Cell Injection Drug Product measure: KL003 engraftment measure: Engraftment time of neutrophil and platelet measure: Overall Survival measure: The number, frequency and severity of adverse events (AE) within 1 year after infusion of KL003 drug products measure: Clonal dominance or secondary tumors caused by lentiviral vector insertional-mutation measure: Numbers of Participants With Vector-Derived Replication-Competent Lentivirus (RCL) measure: The proportion of participants achieved Transfusion Independence (TI)for at least 6 months measure: The proportion of participants achieved TI 12 measure: The start time of Transfusion Independence (TI) after KL003 infusion measure: Total Hb and the vector-derived HbA^T87Q sex: ALL minimumAge: 3 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Ruijin Hospital, Shanghai Jiaotong University School of Medicine city: Shanghai state: Shanghai country: China name: Wei Tang, PhD role: CONTACT phone: +86 13472889588 name: Saijuan Chen, PhD role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 facility: Institute of Hematology & Blood Diseases Hospital city: Tianjin state: Tianjin country: China name: Zhen Gao, Master role: CONTACT phone: +86 15522360862 email: Gaozhen@ihcams.ac.cn name: Jun Shi, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06280365 id: 012 briefTitle: MWM Technique in Patients With Knee OA overallStatus: COMPLETED date: 2024-02-19 date: 2024-03-15 date: 2024-03-15 date: 2024-02-28 date: 2024-04-03 name: Okan University class: OTHER briefSummary: The aim of this study is to investigate the effect of the MWM technique on pain, normal joint movement, proprioception and quality of life in patients with knee osteoarthritis (OA). conditions: Mobilization studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 30 type: ACTUAL name: Mulligan Mobilization with Movement Technique measure: Visual Analog Scale (VAS) measure: Short form-36 (SF-36) measure: Western Ontario and Mcmaster Universities Osteoarthritis Index (WOMAC) measure: Evaluation of proprioception measure: The range of motion sex: ALL minimumAge: 25 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Emine Atıcı city: Tuzla state: İstanbul country: Turkey hasResults: False
nctId: NCT06280352 id: AUVA_Knieathlon_2024 briefTitle: Robotic Assisted vs Custom Made Total Knee Arthroplasty acronym: Knieathlon overallStatus: RECRUITING date: 2024-03-01 date: 2024-12 date: 2026-12 date: 2024-02-28 date: 2024-03-12 name: Austrian Workers Compensation Board Styria class: OTHER briefSummary: The goal of this clinical trial is to compare Robotic Assisted, functionally aligned vs Custom Made Total Knee Arthroplasty in patients with knee osteoarthritis. The main questions it aims to answer are:
* Which system is more OR efficient? Participants will be followed for 2 years postoperatively. conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Custom made Total Knee Arthroplasty name: Functionally aligned robotically assisted total knee arthroplasty measure: Clinical Outcome using the Forgotten Joint Score measure: Clinical outcomes using the Kujala anterior knee pain Score measure: Patient satisfaction measure: Visual analog pain (VAS) scale measure: Surgical and total theatre time measure: Opioid use measure: Number of physiotherapy sessions measure: Range of motion measurements (in degrees) measure: Radiographic data including radiolucent lines measure: Revision rate sex: ALL minimumAge: 40 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AUVA UKH Steiermark Standort Graz status: RECRUITING city: Graz state: Styria zip: 8020 country: Austria name: Antonio Klasan, MD, PHD, EMBA role: CONTACT lat: 47.06667 lon: 15.45 facility: AUVA UKH Steiermark Standort Kalwang status: RECRUITING city: Kalwang state: Styria zip: 8775 country: Austria name: Antonio Klasan, MD, PhD, EMBA role: CONTACT lat: 47.42172 lon: 14.75221 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-11-27 uploadDate: 2024-02-05T09:59 filename: Prot_SAP_000.pdf size: 156436 hasResults: False
nctId: NCT06280339 id: IRB23-0190 briefTitle: Food Cravings Strategies During Dietary Weight Loss overallStatus: RECRUITING date: 2024-01-29 date: 2024-06-01 date: 2024-08-01 date: 2024-02-28 date: 2024-02-28 name: University of Illinois at Urbana-Champaign class: OTHER briefSummary: The purpose is to optimize the EMPOWER program by integrating strategies to reduce food cravings, a critical yet often overlooked factor for long-term success in weight management.
The objective of this study is to determine the efficacy of craving coping strategies on weight loss outcomes by conducting a randomized controlled trial. Participants will be randomized to receive one of the two strategies to manage food cravings. conditions: Obesity conditions: Food Cravings conditions: Weight Loss studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be enrolled in dietary weight loss program. Before the first meeting they will be randomized to one of the two study groups that focus on teaching participants different strategies to cope with food cravings (Inclusion vs. Avoidance).. To ensure balanced representation and meaningful study results, the randomization process will consider specific characteristics, including BMI category, sex, and age. This stratified randomization method helps us compare the effects of the intervention between different groups of participants. primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Test two food cravings strategies during dietary weight loss name: Dietary weight loss program +Food cravings strategies measure: Body weight measure: Food Craving Strategies Compliance measure: Food Cravings measure: Food Cravings measure: Dietary intake sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bevier HAll UIUC status: RECRUITING city: Urbana state: Illinois zip: 61801 country: United States name: Nouf Alfouzan role: CONTACT phone: 217-898-5480 email: noufa2@illinois.edu lat: 40.11059 lon: -88.20727 facility: Bevier HAll UIUC status: RECRUITING city: Urbana state: Illinois zip: 61801 country: United States name: Nouf Alfouzan role: CONTACT phone: 217-898-5480 email: noufa2@illinois.edu name: Manabu Nakamura role: PRINCIPAL_INVESTIGATOR lat: 40.11059 lon: -88.20727 hasResults: False
nctId: NCT06280326 id: Orogastric Tube Removal briefTitle: Effect of Different Materials Used in Orogastric Tube Removal on Skin Condition in Premature Babies overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-05 date: 2024-06-05 date: 2024-08-05 date: 2024-02-28 date: 2024-02-28 name: Ondokuz Mayıs University class: OTHER briefSummary: While medical adhesives provide fixation of devices and catheters in neonatal intensive care, problems such as disruption of skin integrity are frequently encountered when removed. The study aims to compare the effectiveness of sunflower oil and silicone-based remover spray used during the removal of medical adhesives used in oragastric catheter fixation in preterm babies in the Neonatal Intensive Care Unit in preventing skin damage. conditions: Neonatal Skin Conditions studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled experimental trial primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 86 type: ACTUAL name: Sunflower oil name: Slicone based spray measure: Neonatal Skin Condition Score sex: ALL minimumAge: 32 Weeks maximumAge: 36 Weeks stdAges: CHILD facility: Hatice Uzşen city: Samsun state: Atakum zip: 55100 country: Turkey lat: 41.27976 lon: 36.3361 hasResults: False
nctId: NCT06280313 id: uHCC-STI-TJ01 briefTitle: Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension overallStatus: RECRUITING date: 2024-03-15 date: 2027-03-15 date: 2028-03-15 date: 2024-02-28 date: 2024-04-10 name: Zhiyong Huang class: OTHER name: Wuhan Union Hospital, China name: Wuhan University name: Renmin Hospital of Wuhan University name: Taihe Hospital name: Hubei Cancer Hospital name: Xiangyang Central Hospital name: Wuhan Central Hospital name: Yichang Third Renmin Hospital briefSummary: Currently, the combination of targeted therapy and immunotherapy is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, a subset of HCC patients with severe splenomegaly, splenic hyperfunction, and esophagogastric varices due to liver cirrhosis and portal hypertension may be unable to undergo or sustain the combination therapy, ultimately missing the optimal treatment window. Prior studies have indicated that splenectomy can significantly improve liver function and hepatic reserve in cirrhotic patients. It also addresses splenic hyperfunction and reduces the risk of bleeding from esophagogastric varices by combining splenectomy with devascularization around the cardia. Additionally, splenectomy contributes to the improvement of liver fibrosis and restoration of immune function in cirrhotic patients. This study aims to elucidate the impact of splenectomy on the efficacy of combination targeted and immunotherapy in unresectable HCC patients with cirrhotic portal hypertension, particularly those with poor liver function, significant splenic hyperfunction, and severe esophagogastric varices. The research also seeks to explore whether changes in the tumor immune microenvironment before and after splenectomy can influence the effectiveness of immunotherapy. Ultimately, the goal is to provide therapeutic opportunities for this specific patient population. conditions: Unresectable Hepatocellular Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Splenectomy+Targeted therapy+ Immunotherapy measure: Objective Response Rate (ORR) measure: Overall Survival (OS) measure: Progression Free Survival (PFS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tongji Hospital status: RECRUITING city: Wuhan state: Hubei zip: 430000 country: China name: Zhiyong Huang role: CONTACT phone: 86-13995507729 email: Zyhuang126@126.com name: Erlei Zhang role: CONTACT email: baiyu19861104@163.com lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06280300 id: UVMMC2203 briefTitle: Multi-disciplinary Care for Brain Metastases overallStatus: RECRUITING date: 2023-11-16 date: 2024-11-01 date: 2025-11-01 date: 2024-02-28 date: 2024-02-28 name: University of Vermont Medical Center class: OTHER briefSummary: This is a health services intervention study aimed at understanding the impact of intensive multi-disciplinary care compared with standard care on patient-reported symptom outcomes and prognostic awareness in patients with brain metastases. conditions: Brain Metastases, Adult studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: cohort study primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 40 type: ESTIMATED name: health services intervention measure: Patient reported outcomes measure: Feasibility measure: Patient understanding of prognosis measure: survival measure: Exploratory survival outcome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Vermont Medical Center status: RECRUITING city: Burlington state: Vermont zip: 05401 country: United States lat: 44.47588 lon: -73.21207 hasResults: False
nctId: NCT06280287 id: FAPI-PLAQUE briefTitle: PET Imaging of Fibroblast Activation in Atherosclerosis overallStatus: RECRUITING date: 2021-08-01 date: 2024-12-31 date: 2025-12-31 date: 2024-02-28 date: 2024-02-28 name: Peking Union Medical College Hospital class: OTHER briefSummary: Fibroblast activation protein (FAP) is a fibroblast-specific marker expressed in atherosclerosis, associated with endothelial-to-mesenchymal transition and a rupture-prone plaque phenotype. This study aims to evaluate in-vivo fibroblast activation in carotid and coronary atherosclerotic diseases with FAPI PET and its correlation with histological vulnerability and clinical outcome. conditions: Atherosclerosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: FAPI PET measure: SUVmax of atherosclerotic plaque in carotid or coronary arteries measure: TBR of atherosclerotic plaque in carotid or coronary arteries sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking Union Medical College Hospital status: RECRUITING city: Beijing state: Beijing zip: 100730 country: China name: Li Huo role: CONTACT phone: 86-13910801986 email: huoli@pumch.cn lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06280274 id: STUDY00025798 briefTitle: Metformin Use in Patients Undergoing Total Joint Replacement Surgery overallStatus: NOT_YET_RECRUITING date: 2024-02-26 date: 2025-05-30 date: 2025-05-30 date: 2024-02-28 date: 2024-03-01 name: Oregon Health and Science University class: OTHER briefSummary: The goal of this pilot, randomized, single-blind, placebo-controlled trial is to evaluate the feasibility of and provide preliminary information for a multi-center randomized controlled trial that will assess the effects of metformin on blood sugar control in patients after total hip or total knee replacement surgery.
Secondarily, the investigators aim to obtain preliminary estimates of group-specific outcome means and variances for primary and secondary outcomes of a larger future trial. conditions: Hyperglycemia studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: Metformin name: Placebo measure: Rate of participant enrollment measure: Rate of appropriate study drug administration measure: Rate of participant adherence to trial intervention per protocol measure: Rate of participant retention to 90-day follow up measure: Perioperative glycemic variability measure: Sliding scale insulin utilization measure: Hospital length of stay measure: 90-day Rate of surgical site infection measure: 90-day Rate of periprosthetic joint infection measure: 90-day Rate of mortality measure: 90-day rate of readmission sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Oregon Health & Science University city: Portland state: Oregon zip: 97239 country: United States name: Ryland Kagan role: CONTACT phone: 503-494-5649 email: kagan@ohsu.edu lat: 45.52345 lon: -122.67621 hasResults: False
nctId: NCT06280261 id: GO20/296 briefTitle: The Struggle That Is Phenylketonuria : What Do The Patients and Caregivers Suffer From overallStatus: COMPLETED date: 2020-05-27 date: 2020-09-01 date: 2020-09-01 date: 2024-02-28 date: 2024-02-28 name: Hacettepe University class: OTHER briefSummary: Objective: To assess the stress levels and life hardships of phenylketonuria patients and their parents. conditions: Psychological Well-Being conditions: Caregiver Burden conditions: Life Stress studyType: OBSERVATIONAL observationalModel: FAMILY_BASED timePerspective: PROSPECTIVE count: 156 type: ACTUAL name: parenting stress index, Zarit burden scale, Rosenberg self esteem scale, stait trait anxiety inventory, struggles and difficulties questionnaire measure: Rosenberg Self-Esteem Scale measure: Stait trait anxiety inventory measure: Strenghts and difficulties questionnaire measure: Zarit burden scale measure: Parenting stress index sex: ALL minimumAge: 6 Months maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Hacettepe University city: Ankara state: Sihhiye zip: 06100 country: Turkey lat: 39.91987 lon: 32.85427 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2020-10-20 uploadDate: 2024-02-19T08:48 filename: Prot_SAP_000.pdf size: 288978 hasResults: False
nctId: NCT06280248 id: EUS in pancreatic fluid briefTitle: EUS Guided Drainage of Post Pancreatitis Pancreatic Fluid Collection overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-03 date: 2026-06 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: The number as well as the caliber of plastic stents used for EUS-guided PFC drainage are controversial in current practice \[Lin et al., 2014\]. The timing of necrosectomy in WOPN drainage continues to be debated. To date, no comparative studies have been conducted to investigate the ideal timing for stent removal. Thus, the aim of our study is to:
* Compare between early vs late intervention for complete endoscopic necrosectomy of WOPN as regard technical success rates, clinical success rates, potential complications and number of sessions needed. conditions: Pancreas Pseudocyst studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst measure: Complete resolution or a decrease in the sizes of pancreatic fluid collections (PFCs) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06280235 id: 1447-0005 id: U1111-1297-3126 type: REGISTRY domain: WHO International Clinical Trials Registry Platform (ICTRP) id: 2023-507942-10-00 type: REGISTRY domain: CTIS briefTitle: A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine overallStatus: RECRUITING date: 2024-03-07 date: 2025-08-12 date: 2025-10-03 date: 2024-02-28 date: 2024-04-16 name: Boehringer Ingelheim class: INDUSTRY briefSummary: This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
The participants answer questions about their depression symptoms. The results are compared between the groups. The doctors also regularly check the general health of participants. conditions: Depressive Disorder, Major studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 204 type: ESTIMATED name: BI 1569912 name: Placebo measure: Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 8 measure: Change from baseline in MADRS total score at Week 6 measure: Response defined as ≥50% MADRS reduction from baseline at Day 8 measure: Response defined as ≥50% MADRS reduction from baseline at Week 6 measure: Remission defined as MADRS total score ≤10 at Week 6 measure: Change from baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) total score at Day 8 measure: Change from baseline in SMDDS total score at Week 4 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hassman Research Institute status: RECRUITING city: Marlton state: New Jersey zip: 08053 country: United States name: Boehringer Ingelheim role: CONTACT phone: 833-602-2368 email: unitedstates@bitrialsupport.com lat: 39.89122 lon: -74.92183 facility: Neurobehavioral Research, Inc. status: RECRUITING city: Cedarhurst state: New York zip: 11516 country: United States name: Boehringer Ingelheim role: CONTACT phone: 833-602-2368 email: unitedstates@bitrialsupport.com lat: 40.62288 lon: -73.7243 facility: Sooner Clinical Research status: RECRUITING city: Oklahoma City state: Oklahoma zip: 73112 country: United States name: Boehringer Ingelheim role: CONTACT phone: 833-602-2368 email: unitedstates@bitrialsupport.com lat: 35.46756 lon: -97.51643 facility: Grayline Research Center status: RECRUITING city: Wichita Falls state: Texas zip: 76309 country: United States name: Boehringer Ingelheim role: CONTACT phone: 833-602-2368 email: unitedstates@bitrialsupport.com lat: 33.91371 lon: -98.49339 hasResults: False